Human myeloid leukemia cells respond to 12-tetradecanoylphorbol-13-acetate
(TPA) and other activators of protein kinase C (PKC) with the induction of
terminal monocytic differentiation, The present studies demonstrate that TP
A treatment of U-937 leukemia cells is associated with release of mitochond
rial cytochrome c, activation of caspase-3 and induction of internucleosoma
l DNA fragmentation. By contrast, the TUR cell variant, which is deficient
in PKC beta, failed to respond to TPA with release of cytochrome c and indu
ction of the caspase-3 cascade. Moreover, stable overexpression of PKC beta
in TUR cells reconstituted sensitivity to TPA-induced cytochrome c release
and activation of caspase-3, The results also demonstrate that treatment o
f cells with the caspase inhibitor z-VAD-fmk blocks both TPA-induced apopto
sis and monocytic differentiation, Similar results were obtained in U-937 c
ells stably expressing the CrmA caspase inhibitor. These findings demonstra
te that TPA induces cytochrome c release by a PKC beta-dependent mechanism
and that activation of caspase-mediated signaling is required for induction
of the differentiated monocytic phenotype.